Literature DB >> 17004050

[Link between rheumatoid arthritis and cancer].

P Whelan1.   

Abstract

Because it is a systemic disorder, rheumatoid arthritis (RA) is known to predispose affected individuals to other organ manifestations as well as arthritic problems. The serious complications include pericarditis, pulmonary and cutaneous nodules, episcleritis, and rheumatoid vasculitis. Of late, a significantly increased incidence of lymphoma has also accumulated. The overall risk is about double than in the general population, but that in patients with the most severe arthritis is dramatically higher. Men with RA appear to have an extremely elevated risk of Hodgkin's disease, which has also been observed at a higher incidence among the children of affected patients. These lymphomas are not typically infected with EBV, though RA patients have a defective capacity to control systemic EBV infection. Increasing attention is being paid to the effect of RA treatments on development of lymphoma, and some patients with EBV-positive tumors who have been taking methotrexate have shown a positive response after just discontinuing this drug. More controversial is the question of whether anti-TNF alpha agents involve an increased risk of lymphoma; in light of the conflicting evidence this matter is still unresolved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004050     DOI: 10.1007/s00393-006-0105-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  31 in total

1.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Authors:  Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2006-03

2.  Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis.

Authors:  H A Isomäki; T Hakulinen; U Joutsenlahti
Journal:  J Chronic Dis       Date:  1978

Review 3.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

4.  Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

Authors:  Eliza F Chakravarty; Kaleb Michaud; Frederick Wolfe
Journal:  J Rheumatol       Date:  2005-11       Impact factor: 4.666

5.  High titer of antibody to the Epstein-Barr virus membrane antigen in sera from patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  T Yokochi; A Yanagawa; Y Kimura; Y Mizushima
Journal:  J Rheumatol       Date:  1989-08       Impact factor: 4.666

6.  Cancer and rheumatoid arthritis: epidemiologic considerations.

Authors:  P Prior
Journal:  Am J Med       Date:  1985-01-21       Impact factor: 4.965

Review 7.  Epstein-Barr virus and rheumatoid arthritis.

Authors:  Nathalie Balandraud; Jean Roudier; Chantal Roudier
Journal:  Autoimmun Rev       Date:  2004-07       Impact factor: 9.754

8.  The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.

Authors:  Michael H Schiff; Gino DiVittorio; John Tesser; Roy Fleischmann; Joy Schechtman; Sanford Hartman; Thomas Liu; Alan M Solinger
Journal:  Arthritis Rheum       Date:  2004-06

9.  Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis.

Authors:  Ted R Mikuls; Justin O Endo; Susan E Puumala; Patricia A Aoun; Natalie A Black; James R O'Dell; Julie A Stoner; Eugene C Boilesen; Martin A Bast; Debra A Bergman; Kay M Ristow; Melissa Ooi; James O Armitage; Thomas M Habermann
Journal:  J Clin Oncol       Date:  2006-03-06       Impact factor: 44.544

Review 10.  Epstein-Barr virus, arthritis, and the development of lymphoma in arthritis patients.

Authors:  Margaret F C Callan
Journal:  Curr Opin Rheumatol       Date:  2004-07       Impact factor: 5.006

View more
  2 in total

1.  [Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].

Authors:  Jutta G Richter; Pascal Gossen; Ulrich Germing; Sabine Blum; Barbara Hildebrandt; Stefan Braunstein; Dörte Huscher; Matthias Schneider
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

2.  Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic Naive.

Authors:  Emily McKeown; Janet E Pope; Suzanne Leaf
Journal:  Open Rheumatol J       Date:  2009-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.